INAB IN8bio, Inc
Price Chart
Executive Summary
IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting advances in gamma-delta T cell engineering and combination therapies. The publication is a non-clinical, academic milestone that does not provide new clinical data or regulatory catalysts, and is unlikely to materially impact the stock.
Actionable Insight
This press release is a routine scientific publication with no immediate trading catalyst. Monitor for upcoming clinical data readouts or regulatory milestones for INB-100, INB-200/400, or INB-600 platform.
Key Facts
- Review article published in Nature Communications, co-authored by IN8bio CSO Lawrence Lamb, Ph.D.
- Publication discusses gamma-delta T cell engineering, combination strategies, and clinical development approaches.
- No new clinical data, regulatory decisions, or financial guidance were announced.
- IN8bio is a clinical-stage biopharmaceutical company with a market cap of approximately $15M.
Financial Impact
No financial impact; the publication is a non-commercial academic review.
Risk Factors
- No new clinical data or regulatory catalysts provided.
- Early-stage biotech with limited pipeline and high cash burn risk.
- Historical calibration shows low win rate for high-score calls on INAB; neutral events have performed better.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
9d ago
|
Press Release
| $1.54 $1.54 | · 0.00% | ▼ −0.40% | $1.43 (−7.14%) |
|
Jun 1, 2026
11d ago
|
8-K
| $1.73 $1.56 | ▲ +9.83% | ▲ +9.97% | $1.43 (+17.34%) |
|
Jun 1, 2026
11d ago
|
424B5
| $1.73 $1.56 | ▲ +9.83% | ▲ +9.97% | $1.43 (+17.34%) |
|
May 18, 2026
25d ago
|
S-3/A
| $1.45 $1.57 | ▼ −8.28% | ▼ −7.24% | $1.43 (+1.38%) |
|
May 7, 2026
5w ago
|
8-K
| $1.58 $1.63 | ▲ +2.85% | ▲ +2.62% | $1.43 (−9.49%) |
|
Mar 26, 2026
11w ago
|
DEFA14A
| $1.41 $1.37 | ▼ −2.84% | ▼ −2.48% | $1.43 (+1.42%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $1.89 $2.06 | ▲ +8.99% | ▲ +7.97% | $1.43 (−24.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access